NO20081112L - Vevsbeskyttende peptider og anvendelse derav - Google Patents

Vevsbeskyttende peptider og anvendelse derav

Info

Publication number
NO20081112L
NO20081112L NO20081112A NO20081112A NO20081112L NO 20081112 L NO20081112 L NO 20081112L NO 20081112 A NO20081112 A NO 20081112A NO 20081112 A NO20081112 A NO 20081112A NO 20081112 L NO20081112 L NO 20081112L
Authority
NO
Norway
Prior art keywords
tissue
peptides
protecting
receptor
protective
Prior art date
Application number
NO20081112A
Other languages
English (en)
Inventor
Michael Brines
Thomas Coleman
Anthony Cerami
Original Assignee
Araim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araim Pharmaceuticals Inc filed Critical Araim Pharmaceuticals Inc
Publication of NO20081112L publication Critical patent/NO20081112L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Foreliggende oppfinnelse er rettet mot nye vevsbeskyttende peptider. De vevsbeskyttende peptidene ifølge oppfinnelsen kan bindes til et vevsbeskyttende reseptorkompleks. Nærmere bestemt er den foreliggende oppfinnelse rettet mot vevsbeskyttende peptider avledet fra eller som har felles konsensus-sekvenser med deler av cytokin reseptor ligander, innbefattet erytropoietin (EPO), som ikke deltar i bindingen av liganden til reseptorkomplekset, for eksempel til EPO reseptor homodimeren. De vevsbeskyttende peptidene ifølge oppfinnelsen er følgelig avledet fra aminosyre sekvensene i områder av cytokin reseptor ligandene som generelt ligger på eller innenfor det området i ligandproteinet som er motsatt rettet av reseptorkomplekset, dvs at de generelt er avledet fra aminosyresekvenser i områder i ligandproteinet som er rettet bort fra reseptorkomplekset når liganden er bundet til reseptoren. Oppfinnelsen er videre rettet mot konsensus-sekvensene for anvendelse ved utfonning av et syntetisk vevsbeskyttende peptid. Disse vevsbeskyttende peptidene omfatter også fragmenter, kimærer samt peptider utformet for å etterlikne den rommelige lokalisering av viktige aminosyrerester i de vevsbeskyttende reseptorligandene, for eksempel EPO. Oppfinnelsen omfatter videre fremgangsmåter for behandling eller forebyggelse av en sykdom eller forstyrrelse ved anvendelse av vevsbeskyttende peptider ifølge foreliggende oppfinnelse. Oppfinnelsen omfatter også fremgangsmåter for å fremme funksjonen av eksiterbare vev ved anvendelse av vevsbeskyttende peptider ifølge foreliggende oppfinnelse.
NO20081112A 2005-08-05 2008-03-03 Vevsbeskyttende peptider og anvendelse derav NO20081112L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70574105P 2005-08-05 2005-08-05
US70627605P 2005-08-08 2005-08-08
US83173706P 2006-07-18 2006-07-18
PCT/US2006/031061 WO2007019545A2 (en) 2005-08-05 2006-08-07 Tissue protective peptides and uses thereof

Publications (1)

Publication Number Publication Date
NO20081112L true NO20081112L (no) 2008-05-05

Family

ID=37728020

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081112A NO20081112L (no) 2005-08-05 2008-03-03 Vevsbeskyttende peptider og anvendelse derav

Country Status (26)

Country Link
US (7) US8071554B2 (no)
EP (5) EP2594279B1 (no)
JP (6) JP5274253B2 (no)
KR (7) KR20190084136A (no)
CN (2) CN103724418B (no)
AU (1) AU2006278264B2 (no)
BR (1) BRPI0614529A8 (no)
CA (3) CA2618396C (no)
DK (3) DK2371855T3 (no)
EA (1) EA015672B1 (no)
ES (3) ES2653864T3 (no)
HK (1) HK1127751A1 (no)
HU (3) HUE026444T2 (no)
IL (3) IL189287A (no)
IN (1) IN2014CN02050A (no)
LT (2) LT2540309T (no)
MX (3) MX2008001509A (no)
NO (1) NO20081112L (no)
NZ (1) NZ565937A (no)
PL (3) PL2540309T3 (no)
PT (3) PT2540309T (no)
SG (2) SG10201805825SA (no)
SI (3) SI2540309T1 (no)
UA (1) UA100222C2 (no)
WO (1) WO2007019545A2 (no)
ZA (1) ZA201101890B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) * 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
PT2540309T (pt) 2005-08-05 2017-12-29 Araim Pharmaceuticals Inc Péptidos protectores de tecidos e suas utilizações
MX2008015392A (es) * 2006-06-07 2009-05-05 Univ Tokushima Tratamiento de enfermedades isquemicas que usan eritropoyetina.
WO2008058942A2 (en) * 2006-11-13 2008-05-22 Charite - Universitätsmedezin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
SG188161A1 (en) * 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2012051581A2 (en) * 2010-10-14 2012-04-19 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
US9566349B2 (en) * 2010-10-14 2017-02-14 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
CN102180948A (zh) * 2011-03-03 2011-09-14 复旦大学附属中山医院 一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) * 2011-05-05 2014-04-30 中国人民解放军第三军医大学 小分子多肽和小分子多肽脂质体及其运用
US20140178335A1 (en) * 2011-07-27 2014-06-26 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
WO2013042118A1 (en) * 2011-09-20 2013-03-28 A.A. Cash Technology Ltd Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (en) 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
WO2015009820A2 (en) * 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN104744593A (zh) * 2013-12-25 2015-07-01 深圳先进技术研究院 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) * 2014-05-13 2015-11-24 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105837663A (zh) * 2014-06-22 2016-08-10 马恒标 组织保护活性多肽sl10及其应用
CN108347916B (zh) 2015-10-14 2022-02-08 先时迈纳米生物科技股份有限公司 一种减少冰晶形成的组合物及其方法
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
PL3538065T3 (pl) 2016-11-10 2023-12-04 Asc Regenity Ltd. Formulacje kosmetyczne do zastosowań miejscowych zawierające cząsteczki pochodzące z erytropoetyny
WO2018155997A1 (ko) * 2017-02-27 2018-08-30 재단법인 대구경북과학기술원 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2018157773A1 (zh) 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2019199661A1 (en) * 2018-04-08 2019-10-17 Brim Biotechnology, Inc. Application of pedf-derived short peptides in tendon healing
KR102300060B1 (ko) 2018-06-12 2021-09-08 주식회사 엘지에너지솔루션 2열 터미널 구조의 pcb 다이렉트 커넥터
AU2019337564A1 (en) 2018-09-10 2021-05-06 Cold Spring Harbor Laboratory Methods for treating pancreatitis
CN112390877B (zh) * 2019-08-16 2022-10-04 董红燕 Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
CN118255845A (zh) * 2022-12-27 2024-06-28 上海瑞吉康生物医药有限公司 相分离逆转多肽的变体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4558006A (en) * 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5498694A (en) 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6140120A (en) * 1993-02-12 2000-10-31 Board Of Trustees Of Leland Stanford Jr. University Regulated transcription of targeted genes and other biological events
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
HUP9901069A2 (hu) * 1995-06-07 1999-07-28 Affymax Technologies, N.V. Az eritropoietin receptorhoz kötődő vegyületek és peptidek
JP2001524944A (ja) * 1997-03-05 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 神経障害性疼痛の緩和方法
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
NZ514690A (en) * 1999-04-13 2004-07-30 Kenneth S Modulation of excitable tissue function by peripherally administered erythropoietin
WO2001083548A1 (fr) * 2000-04-28 2001-11-08 Effector Cell Institute Nouveau derive de facteur chimiotactique cellulaire
ES2361824T3 (es) * 2000-12-20 2011-06-22 F. Hoffmann-La Roche Ag Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
CA2437272A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified erythropoietin (epo) with reduced immunogenicity
WO2002085940A2 (en) * 2001-04-04 2002-10-31 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
PL374580A1 (en) 2002-07-01 2005-10-31 The Kenneth S.Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
KR100478455B1 (ko) 2002-08-19 2005-03-22 삼성전자주식회사 전자렌지
AU2003273297A1 (en) 2002-09-09 2004-03-29 Kenneth S. Warren Institute, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
JP2004305006A (ja) * 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
CN1812800B (zh) * 2003-04-25 2013-01-16 匹兹堡大学 用于促进和增强神经修复和再生的肌肉来源的细胞(mdc)
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US8329652B2 (en) 2005-05-10 2012-12-11 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
PT2540309T (pt) 2005-08-05 2017-12-29 Araim Pharmaceuticals Inc Péptidos protectores de tecidos e suas utilizações
EP2960341B1 (en) 2007-11-29 2018-06-27 Molecular Health GmbH Novel tissue protective erythropoietin receptor (nepor) and methods of use
SG188161A1 (en) 2008-01-22 2013-03-28 Araim Pharmaceuticals Inc Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CA2725601A1 (en) * 2008-04-28 2009-11-05 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2011022056A2 (en) 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

Also Published As

Publication number Publication date
SI2594279T1 (en) 2018-04-30
KR101626153B1 (ko) 2016-06-01
BRPI0614529A8 (pt) 2016-07-12
US9340598B2 (en) 2016-05-17
ZA201101890B (en) 2012-12-27
IL261346A (en) 2018-10-31
US8716245B2 (en) 2014-05-06
IL189287A0 (en) 2008-06-05
ES2653790T3 (es) 2018-02-08
DK2371855T3 (en) 2015-09-21
CA2618396C (en) 2018-02-27
US20190016769A1 (en) 2019-01-17
EP2540309B1 (en) 2017-11-22
HUE035655T2 (en) 2018-05-28
US20150152156A1 (en) 2015-06-04
HUE026444T2 (en) 2016-05-30
WO2007019545A2 (en) 2007-02-15
BRPI0614529A2 (pt) 2011-08-09
MX339613B (es) 2016-06-02
US20160244498A1 (en) 2016-08-25
US8673861B2 (en) 2014-03-18
US20140323401A1 (en) 2014-10-30
PL2371855T3 (pl) 2015-12-31
KR20180116475A (ko) 2018-10-24
EP1924276A2 (en) 2008-05-28
EP2371855B1 (en) 2015-07-22
JP2015134772A (ja) 2015-07-27
ES2550055T3 (es) 2015-11-04
US20120142595A1 (en) 2012-06-07
KR20170027868A (ko) 2017-03-10
JP5918155B2 (ja) 2016-05-18
IL189287A (en) 2015-07-30
CA3079319A1 (en) 2007-02-15
JP2018134084A (ja) 2018-08-30
KR20080064800A (ko) 2008-07-09
IL239695A0 (en) 2015-08-31
JP6491621B2 (ja) 2019-03-27
JP5274253B2 (ja) 2013-08-28
JP6158235B2 (ja) 2017-07-05
CN103724418B (zh) 2018-03-06
JP2013126995A (ja) 2013-06-27
JP2009508471A (ja) 2009-03-05
SG2014007868A (en) 2014-05-29
PT2594279T (pt) 2017-12-29
CN101378772B (zh) 2013-12-04
CN101378772A (zh) 2009-03-04
MX364100B (es) 2019-04-12
JP2020078317A (ja) 2020-05-28
KR20180067735A (ko) 2018-06-20
US10100096B2 (en) 2018-10-16
EP2371855A1 (en) 2011-10-05
CA2618396A1 (en) 2007-02-15
EP2540309A3 (en) 2013-05-29
AU2006278264A1 (en) 2007-02-15
KR20130080481A (ko) 2013-07-12
ES2653864T3 (es) 2018-02-09
KR101713368B1 (ko) 2017-03-07
PT2371855E (pt) 2015-11-03
EP2540309A2 (en) 2013-01-02
US8071554B2 (en) 2011-12-06
PL2594279T3 (pl) 2018-03-30
SI2540309T1 (en) 2018-04-30
KR20190084136A (ko) 2019-07-15
KR20200072568A (ko) 2020-06-22
CA2982909A1 (en) 2007-02-15
EP2594279A1 (en) 2013-05-22
US20090221482A1 (en) 2009-09-03
EP2594279B1 (en) 2017-11-22
EA200800536A1 (ru) 2009-02-27
DK2540309T3 (en) 2018-01-08
HK1127751A1 (en) 2009-10-09
IN2014CN02050A (no) 2015-05-29
DK2594279T3 (en) 2018-01-08
US20120264682A1 (en) 2012-10-18
PL2540309T3 (pl) 2018-03-30
UA100222C2 (uk) 2012-12-10
LT2594279T (lt) 2018-01-10
SG10201805825SA (en) 2018-08-30
CN103724418A (zh) 2014-04-16
NZ565937A (en) 2011-09-30
MX2008001509A (es) 2008-04-04
PT2540309T (pt) 2017-12-29
SI2371855T1 (sl) 2015-11-30
JP2016196480A (ja) 2016-11-24
HUE035793T2 (en) 2018-05-28
LT2540309T (lt) 2018-01-10
EP3363451A1 (en) 2018-08-22
EA015672B1 (ru) 2011-10-31
WO2007019545A3 (en) 2008-10-02
EP1924276A4 (en) 2009-07-22
AU2006278264B2 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
NO20081112L (no) Vevsbeskyttende peptider og anvendelse derav
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
HK1151039A1 (en) Kdr peptides and vaccines comprising the same kdr kdr
WO2010135491A3 (en) Fibroblast growth factor mutants having improved functional half-life and methods of their use
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
WO2005087811A3 (en) Estrogen receptors and methods of use
ATE509096T1 (de) Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
MX2021011726A (es) Escindasas modificadas, usos de las mismas y kits relacionados.
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
EP2589658A4 (en) PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN
BRPI0412607A (pt) método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
FI20050753A (fi) Uudet peptidit
ATE501256T1 (de) Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
WO2005004894A3 (en) Methods for increasing cell and tissue viability
AU2003302901A8 (en) Human recombinant endooligopeptidase a (heopa)
WO2007073845A3 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
EP3219720A3 (en) Wdrpuh epitope peptides and vaccines containing the same
SE9801530D0 (sv) Method for screening
Pyoung et al. Characterization of the 36kDa Sperminogen by MALDI-MS and Peptide Sequence Analyses in boar Spermatozoa

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application